<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04584645</url>
  </required_header>
  <id_info>
    <org_study_id>2020/08/14</org_study_id>
    <nct_id>NCT04584645</nct_id>
  </id_info>
  <brief_title>A Digital Flu Intervention for People With Cardiovascular Conditions</brief_title>
  <acronym>CardioFlu</acronym>
  <official_title>Increasing Influenza Vaccination in Individuals With Cardiovascular Conditions: Assessing the Effectiveness of a Digital Intervention in a Decentralized Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Evidation Health</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Evidation Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 6-month prospective, digital randomized controlled trial targeting approximately 49,000&#xD;
      individuals to evaluate the effectiveness of an influenza vaccination intervention during&#xD;
      influenza season for people with cardiovascular conditions&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 21, 2020</start_date>
  <completion_date type="Actual">April 12, 2021</completion_date>
  <primary_completion_date type="Actual">April 12, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>A set of existing Achievement members who have previously self-reported to meeting the inclusion criteria will be tagged for study inclusion, termed &quot;participants&quot;. Since participants will be blinded to their study participation status, participants will not be asked to take any action to enroll in the study. In order to identify a target list of participants, Evidation Health will leverage already permissioned information from Achievement members, including data on their cardiovascular diagnoses, age, sex/gender, race/ethnicity, and country of residence.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Differences in rates of self-reported influenza vaccination status after study start between those who receive a targeted digital intervention and those who do not through study close</measure>
    <time_frame>Up to 7 months</time_frame>
    <description>To determine the effectiveness of a digital intervention designed to increase influenza vaccination rates in individuals with cardiovascular diagnoses (CV diagnoses) by examining differences in self-reported influenza vaccination rates between individuals with cardiovascular disease who receive a targeted digital intervention (CVD-I) aimed at increasing influenza vaccination and those with CV diagnoses who received no intervention (CVD-C) by the end of the study period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences in rates of self-reported influenza vaccination status after study start by level of engagement with intervention messages within those who receive a targeted digital intervention through study close</measure>
    <time_frame>Up to 7 months</time_frame>
    <description>Differences in rates of self-reported influenza vaccination status after study start between individuals in the intervention group that completed different numbers of intervention messages (0 to 6 messages) over the course of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in self-reported vaccination rates by engagement with specific intervention messages</measure>
    <time_frame>Up to 7 months</time_frame>
    <description>Differences in rates of self-reported influenza vaccination status between individuals in the group receiving the targeted intervention, between those who did or did not engage with each specific intervention message over the course of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in self-reported perceptions of the intervention messages, by individual message and the intervention overall</measure>
    <time_frame>Up to 7 months</time_frame>
    <description>Difference in self-reported perceptions using a Likert scale (1: It convinced me not to get the flu vaccine of the intervention messages to 5:It convinced me to get the flu vaccine), by individual message and the intervention overall, within the group receiving the digital intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prediction of vaccination status</measure>
    <time_frame>Up to 7 months</time_frame>
    <description>Development of a machine learning model to predict self-reported influenza vaccination status during the flu season September 2020 and April 2021</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11238</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <condition>Atrial Fibrillation</condition>
  <condition>Abnormal Heart Rhythms</condition>
  <condition>Cardiac Arrest</condition>
  <condition>Heart Attack</condition>
  <condition>Myocardial Infarction</condition>
  <condition>Coronary Heart Disease</condition>
  <condition>Heart Failure</condition>
  <condition>Stroke</condition>
  <condition>Cerebrovascular Accident</condition>
  <arm_group>
    <arm_group_label>cardiovascular disorders digital intervention arm (CVD-I)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individuals with cardiovascular disease who receive a targeted digital intervention aimed at increasing influenza vaccination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cardiovascular disorders without digital intervention arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Individuals with cardiovascular disease who receive no intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Targeted digital intervention</intervention_name>
    <description>Messages that provide informational content on the influenza vaccine (sourced from the Centers for Disease Control and Prevention and the American Heart Association), specific information about influenza and cardiovascular disorders, and behavioral prompts (e.g., reminders) surrounding influenza vaccination behaviors.</description>
    <arm_group_label>cardiovascular disorders digital intervention arm (CVD-I)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Resides in the U.S.&#xD;
&#xD;
          -  Speaks, reads, and understands English&#xD;
&#xD;
          -  Has self-reported being diagnosed with any of the following cardiac conditions below&#xD;
             in their Achievement profile:&#xD;
&#xD;
          -  Atrial Fibrillation or Afib&#xD;
&#xD;
          -  Abnormal or irregular heart rhythm, other arrhythmic heart disease&#xD;
&#xD;
          -  Cardiac arrest, or heart attack (myocardial infarction)&#xD;
&#xD;
          -  Coronary heart disease like a heart blockage, treated with medications, a stent in the&#xD;
             heart, or sometimes bypass surgery-&#xD;
&#xD;
          -  Heart failure, like congestive heart failure&#xD;
&#xD;
          -  Stroke or cerebrovascular accident (CVA)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participated in Step 1, Part 2 semi-structured interviews used to obtain feedback on&#xD;
             the intervention messages&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nell Marshall, DrPh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Evidation Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Evidation Health</name>
      <address>
        <city>San Mateo</city>
        <state>California</state>
        <zip>94401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.cdc.gov/flu/vaccines-work/2016-2017.html</url>
    <description>CDC Seasonal Influenza Vaccine Effectiveness</description>
  </link>
  <link>
    <url>https://www.cdc.gov/flu/highrisk/heartdisease.htm</url>
    <description>CDC Flu &amp; Heart Disease and Stroke</description>
  </link>
  <link>
    <url>https://www.cdc.gov/flu/fluvaxview/interactive-help.htm</url>
    <description>CDC FluVaxView Interactive, National Center for Immunization and Respiratory Diseases (NCIRD)</description>
  </link>
  <reference>
    <citation>Dale LP, White L, Mitchell M, Faulkner G. Smartphone app uses loyalty point incentives and push notifications to encourage influenza vaccine uptake. Vaccine. 2019 Jul 26;37(32):4594-4600. doi: 10.1016/j.vaccine.2018.04.018. Epub 2018 Apr 23.</citation>
    <PMID>29699784</PMID>
  </reference>
  <reference>
    <citation>Dos Santos G, Tahrat H, Bekkat-Berkani R. Immunogenicity, safety, and effectiveness of seasonal influenza vaccination in patients with diabetes mellitus: A systematic review. Hum Vaccin Immunother. 2018;14(8):1853-1866. doi: 10.1080/21645515.2018.1446719. Epub 2018 Apr 9.</citation>
    <PMID>29517396</PMID>
  </reference>
  <reference>
    <citation>Doyle JD, Chung JR, Kim SS, Gaglani M, Raiyani C, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Martin ET, Belongia EA, McLean HQ, Foust A, Sessions W, Berman L, Garten RJ, Barnes JR, Wentworth DE, Fry AM, Patel MM, Flannery B. Interim Estimates of 2018-19 Seasonal Influenza Vaccine Effectiveness - United States, February 2019. MMWR Morb Mortal Wkly Rep. 2019 Feb 15;68(6):135-139. doi: 10.15585/mmwr.mm6806a2.</citation>
    <PMID>30763298</PMID>
  </reference>
  <reference>
    <citation>Frank L, Basch E, Selby JV; Patient-Centered Outcomes Research Institute. The PCORI perspective on patient-centered outcomes research. JAMA. 2014 Oct 15;312(15):1513-4. doi: 10.1001/jama.2014.11100.</citation>
    <PMID>25167382</PMID>
  </reference>
  <reference>
    <citation>Healthy People 2020. (2019). Retrieved from https://www.healthypeople.gov/. from Healthy People 2020, United States Department of Health and Human Services, Office of Disease Prevention and Health Promotion, https://www.healthypeople.gov/</citation>
  </reference>
  <reference>
    <citation>Hurley LP, Beaty B, Lockhart S, Gurfinkel D, Breslin K, Dickinson M, Whittington MD, Roth H, Kempe A. RCT of Centralized Vaccine Reminder/Recall for Adults. Am J Prev Med. 2018 Aug;55(2):231-239. doi: 10.1016/j.amepre.2018.04.022. Epub 2018 Jun 15.</citation>
    <PMID>29910118</PMID>
  </reference>
  <reference>
    <citation>Jackson ML, Chung JR, Jackson LA, Phillips CH, Benoit J, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman R, Nowalk MP, Fry AM, Flannery B. Influenza Vaccine Effectiveness in the United States during the 2015-2016 Season. N Engl J Med. 2017 Aug 10;377(6):534-543. doi: 10.1056/NEJMoa1700153.</citation>
    <PMID>28792867</PMID>
  </reference>
  <reference>
    <citation>Lee WN, St√ºck D, Konty K, Rivers C, Brown CR, Zbikowski SM, Foschini L. Large-scale influenza vaccination promotion on a mobile app platform: A randomized controlled trial. Vaccine. 2020 Apr 16;38(18):3508-3514. doi: 10.1016/j.vaccine.2019.11.053. Epub 2019 Nov 29.</citation>
    <PMID>31787410</PMID>
  </reference>
  <reference>
    <citation>Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, Bridges CB. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007 Jun 28;25(27):5086-96. Epub 2007 Apr 20.</citation>
    <PMID>17544181</PMID>
  </reference>
  <reference>
    <citation>Nehme EK, Delphia M, Cha EM, Thomas M, Lakey D. Promoting Influenza Vaccination Among an ACA Health Plan Subscriber Population: A Randomized Trial. Am J Health Promot. 2019 Jul;33(6):916-920. doi: 10.1177/0890117118823157. Epub 2019 Jan 10.</citation>
    <PMID>30630342</PMID>
  </reference>
  <reference>
    <citation>Rolfes MA, Flannery B, Chung JR, O'Halloran A, Garg S, Belongia EA, Gaglani M, Zimmerman RK, Jackson ML, Monto AS, Alden NB, Anderson E, Bennett NM, Billing L, Eckel S, Kirley PD, Lynfield R, Monroe ML, Spencer M, Spina N, Talbot HK, Thomas A, Torres SM, Yousey-Hindes K, Singleton JA, Patel M, Reed C, Fry AM; US Influenza Vaccine Effectiveness (Flu VE) Network, the Influenza Hospitalization Surveillance Network, and the Assessment Branch, Immunization Services Division, Centers for Disease Control and Prevention. Effects of Influenza Vaccination in the United States During the 2017-2018 Influenza Season. Clin Infect Dis. 2019 Nov 13;69(11):1845-1853. doi: 10.1093/cid/ciz075.</citation>
    <PMID>30715278</PMID>
  </reference>
  <reference>
    <citation>Samson, S., Lee, J., Tai, C., &amp; Foschini, L. (2020, September). Digital intervention is effective at increasing influenza vaccination in people living with diabetes. Poster presented at the European Association for the Science of Diabetes in Vienna, Austria - Conference to occur digitally 22-25 September, 2020 due to COVID-19.</citation>
  </reference>
  <reference>
    <citation>Samson SI, Konty K, Lee WN, Quisel T, Foschini L, Kerr D, Liska J, Mills H, Hollingsworth R, Greenberg M, Beal AC. Quantifying the Impact of Influenza Among Persons With Type 2 Diabetes Mellitus: A New Approach to Determine Medical and Physical Activity Impact. J Diabetes Sci Technol. 2021 Jan;15(1):44-52. doi: 10.1177/1932296819883340. Epub 2019 Nov 20.</citation>
    <PMID>31747789</PMID>
  </reference>
  <reference>
    <citation>Zhong B. How to calculate sample size in randomized controlled trial? J Thorac Dis. 2009 Dec;1(1):51-4.</citation>
    <PMID>22263004</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 15, 2020</study_first_submitted>
  <study_first_submitted_qc>October 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiovascular disease</keyword>
  <keyword>Flu</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 18, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT04584645/SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

